Research in recent years has identified molecules capable of rescuing for most CF patients the function of the genetically mutated CFTR protein, responsible for the clinical manifestations of the disease. But not all patients respond effectively to the therapies already proposed. The project aims to identify alternative ways to correct the CFTR protein linked to the F508del mutation more effectively. For this reason, it intends to analyze, with sophisticated procedures, the set of proteins (proteome: 5-7 thousand proteins) of human bronchial cells with F508del mutation, in order to identify those that play key roles in the maturation of the CFTR protein and that could constitute new and more appropriate drug targets to recover CFTR. On such targets the already known drugs will be tested initially, to open then to the possibility of alternative drugs more suitable to the new targets. The outcome expected from this study is a list of new candidates for CF therapy.